ESTRO 2025 - Abstract Book

S379

Brachytherapy - Urology

ESTRO 2025

Results: With a median follow-up of 223 months (range 66-286), 23 patients (26,4%) experienced biochemical recurrence and 22 (25%) had clinical recurrence. The median time to biochemical failure was 65 months (range 24-204). Distant metastasis occurred in 20 patients (23%). No grade 3 or higher late toxicity was observed. Long-term urinary toxicity was absent in 92% of patients, and no patient experienced long-term urinary incontinence or urethral stenosis. Sexual dysfunction developed in 22% of patients. Late rectal toxicity was absent in 98% of patients. Conclusion: HDR-BT combined with EBRT is an effective treatment for VHR-PCa with excellent long-term oncologic outcomes and minimal late toxicity. The exceptionally low rates of biochemical recurrence, distant metastasis, and grade 3 or higher late toxicity for both urinary and gastrointestinal functions strongly support the use of this combination

therapy as a standard treatment option for patients with VHR-PCa. Keywords: prostate cancer, brachytherapy, long-term outcomes